Anika Therapeutics, Inc. (ANIK)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$19.73+3.30%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $264M
- Forward P/E
- 20.8
- 52-week range
- $8.67 – $22.88
- 52-week change
- +106.26%
- EPS (trailing)
- −$0.23
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $113M (−5.91%)
- Net income
- −$11.0M
- Operating margin
- −9.8%
- Diluted EPS
- −$0.76
- Free cash flow
- $4.4M
From the company’s annual report on SEC EDGAR.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation.
Headquarters: Bedford, United States · 235 employees · anika.com